<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mem Inst Oswaldo Cruz</journal-id><journal-id journal-id-type="iso-abbrev">Mem. Inst. Oswaldo Cruz</journal-id><journal-id journal-id-type="pmc-domain-id">2285</journal-id><journal-id journal-id-type="pmc-domain">mioc</journal-id><journal-title-group><journal-title>Mem&#243;rias do Instituto Oswaldo Cruz</journal-title></journal-title-group><issn pub-type="ppub">0074-0276</issn><issn pub-type="epub">1678-8060</issn><publisher><publisher-name>Instituto Oswaldo Cruz</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4501412</article-id><article-id pub-id-type="pmcid-ver">PMC4501412.1</article-id><article-id pub-id-type="pmcaid">4501412</article-id><article-id pub-id-type="pmcaiid">4501412</article-id><article-id pub-id-type="pmid">26018452</article-id><article-id pub-id-type="doi">10.1590/0074-02760140248</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Studies of genotoxicity and mutagenicity of nitroimidazoles: demystifying
this critical relationship with the nitro group</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Boechat</surname><given-names initials="N">N&#250;bia</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="c01">
<sup>+</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carvalho</surname><given-names initials="AS">Alcione S</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Salom&#227;o</surname><given-names initials="K">Kelly</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Castro</surname><given-names initials="SL">Solange L</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Araujo-Lima</surname><given-names initials="CF">Carlos F</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mello</surname><given-names initials="FVC">Francisco VC</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Felzenszwalb</surname><given-names initials="I">Israel</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aiub</surname><given-names initials="CAF">Claudia AF</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Conde</surname><given-names initials="TR">Taline Ramos</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zamith</surname><given-names initials="HPS">Helena PS</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Skupin</surname><given-names initials="R">Rolf</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haufe</surname><given-names initials="G">G&#252;nter</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Departamento de S&#237;ntese de F&#225;rmacos, Farmanguinhos</aff><aff id="aff2"><label>2</label>Laborat&#243;rio de Biologia Celular, Instituto Oswaldo Cruz</aff><aff id="aff3"><label>3</label>Departamento de Biof&#237;sica e Biometria, Universidade do Estado do Rio de
Janeiro, Rio de Janeiro, RJ, Brasil</aff><aff id="aff4"><label>4</label>Departamento de Gen&#233;tica e Biologia Molecular, Universidade Federal do
Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brasil</aff><aff id="aff5"><label>5</label>Departamento de Farmacologia e Toxicologia, Instituto Nacional de
Controle de Qualidade em Sa&#250;de, Funda&#231;&#227;o Oswaldo Cruz, Rio de Janeiro, RJ, Brasil</aff><aff id="aff6"><label>6</label>Organisch-Chemisches Institut, Westf&#228;lischen Wilhelms-Universit&#228;t
M&#252;nster, M&#252;nster, Germany</aff><author-notes><corresp id="c01"><label>+</label> Corresponding author: <email>boechat@far.fiocruz.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>6</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2015</year></pub-date><volume>110</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">255338</issue-id><fpage>492</fpage><lpage>499</lpage><history><date date-type="received"><day>23</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2015</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2015</year></date></event><event event-type="pmc-live"><date><day>16</day><month>07</month><year>2015</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2015-07-17 00:08:36.473"><day>17</day><month>07</month><year>2015</year></date></event></pub-history><permissions><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="0074-0276-mioc-110-4-0492.pdf"/><abstract><p>Nitroimidazoles exhibit high microbicidal activity, but mutagenic, genotoxic and
cytotoxic properties have been attributed to the presence of the nitro group.
However, we synthesised nitroimidazoles with activity against the trypomastigotes of
<italic toggle="yes">Trypanosoma cruzi</italic>, but that were not genotoxic. Herein,
nitroimidazoles (11-19) bearing different substituent groups were investigated for
their potential induction of genotoxicity (comet assay) and mutagenicity
(<italic toggle="yes">Salmonella</italic>/Microsome assay) and the correlations of these
effects with their trypanocidal effect and with megazol were investigated. The
compounds were designed to analyse the role played by the position of the nitro group
in the imidazole nucleu<italic toggle="yes">s (C-4 or C-5)</italic> and the presence of oxidisable
groups at N-1 as an anion receptor group and the role of a methyl group at C-2.
Nitroimidazoles bearing NO2 at C-4 and CH3 at C-2 were not genotoxic compared to
those bearing NO<italic toggle="yes"><sub>2</sub></italic> at C-5. However, when there was a CH3
at C-2, the position of the NO2 group had no influence on the genotoxic activity.
Fluorinated compounds exhibited higher genotoxicity regardless of the presence of CH3
at C-2 or NO2 at C-4 or C-5. However, in compounds 11 (2-CH3; 4-NO2; N-CH2OHCH2Cl)
and 12 (2-CH3; 4-NO2; N-CH2OHCH2F), the fluorine atom had no influence on
genotoxicity. This study contributes to the future search for new and safer
prototypes and provide.</p></abstract><kwd-group><kwd>nitroimidazoles</kwd><kwd>genotoxicity</kwd><kwd>mutagenicity</kwd><kwd>trypanocidal activity</kwd></kwd-group><counts><fig-count count="5"/><table-count count="2"/><equation-count count="0"/><ref-count count="61"/><page-count count="1"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The class of nitroimidazoles includes compounds that are important antiparasitic agents,
which have a broad spectrum of action and high biological activity. For instance,
metronidazole (1), secnidazole (2), tinidazole (3), ornidazole (4), dimetridazole (5),
carnidazole (6) and panidazole (7) (<xref rid="f01" ref-type="fig">Fig. 1</xref>) are some
examples of drugs currently used to treat infections of anaerobic
<italic toggle="yes">Bacteroides</italic> sp. and protozoans, such as <italic toggle="yes">Trichomonas
</italic>sp., <italic toggle="yes">Entamoeba </italic>sp., <italic toggle="yes">Giardia </italic>sp. and
<italic toggle="yes">Histomonas </italic>sp. (<xref rid="B60" ref-type="bibr">Yakugaku 1971</xref>,
<xref rid="B58" ref-type="bibr">William et al. 1975</xref>, <xref rid="B10" ref-type="bibr">Buschini et al. 2007</xref>, <xref rid="B35" ref-type="bibr">Mital
2009</xref>, <xref rid="B52" ref-type="bibr">Valdez et al. 2009</xref>). In addition,
nitroimidazoles have other interesting properties, including antitubercular and antifungal
activities, in the control of fertility (<xref rid="B8" ref-type="bibr">Bone et al.
1997</xref>, <xref rid="B16" ref-type="bibr">Cooper et al. 1997</xref>), as
radiosensitisers (<xref rid="B40" ref-type="bibr">Paul &amp; Abdel-Nabi 2007</xref>, <xref rid="B28" ref-type="bibr">Khabnadideh et al. 2009</xref>, <xref rid="B31" ref-type="bibr">Lee et al. 2011)</xref> and against the recombinant reverse transcriptase of
human immunodeficiency virus (HIV)-1 (<xref rid="B46" ref-type="bibr">Silvestri et al.
2002</xref>, <xref rid="B2" ref-type="bibr">Al-Soud et al. 2007</xref>).</p><p>
<fig id="f01" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>: structures of the nitroimidazole drugs (1-7).</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="0074-0276-mioc-110-4-0492-gf01.jpg"/></fig>
</p><p>The 2-nitroimidazole benznidazole (BZ) (8) (<xref rid="f02" ref-type="fig">Fig. 2</xref>)
and nifurtimox (NFX) are the only available drugs for the treatment of Chagas disease.
However, these nitro derivatives exhibit poor activity in the late chronic phase, with
severe collateral effects and limited efficacy against different parasitic isolates,
justifying the urgent need to identify alternatives to treat chagasic patients (Soeiro
&amp; de Castro 2011, <xref rid="B51" ref-type="bibr">Urbina 2014)</xref>. This disease is
caused by <italic toggle="yes">Trypanosoma cruzi</italic> and affects approximately eight million
individuals in Latin America. Furthermore, it is emerging in nonendemic areas, associated
with the immigration of infected individuals (<xref rid="B25" ref-type="bibr">Gascon et al.
2010</xref>, <xref rid="B45" ref-type="bibr">Schmunis &amp; Yadon 2010</xref>, <xref rid="B24" ref-type="bibr">Fran&#231;a et al. 2014</xref>). Megazol (9) (<xref rid="f02" ref-type="fig">Fig. 2</xref>) is a nitroimidazole-thiadiazole with high in vitro and in
vivo activity against <italic toggle="yes">Trypanosoma cruzi</italic>, including against strains
resistant to 8 (<xref rid="B23" ref-type="bibr">Filardi &amp; Brener 1982, d</xref>, de
Castro &amp; de Meirelles 1986, <xref rid="B30" ref-type="bibr">Lages-Silva et al.
1990</xref>, <xref rid="B44" ref-type="bibr">Salom&#227;o et al. 2010</xref>) and
<italic toggle="yes">Trypanosoma brucei</italic>, the causative agent of human African
trypanosomiasis (HAT) (<xref rid="B19" ref-type="bibr">Enanga et al. 1998</xref>, <xref rid="B20" ref-type="bibr">2000</xref>, <xref rid="B6" ref-type="bibr">Boda et al.
2004)</xref>. The mode of action of 9 is associated with the interference with the
parasite&#8217;s oxygen metabolism, as well as acting as a trypanothione scavenger (<xref rid="B53" ref-type="bibr">Viod&#233; et al. 1999</xref>, <xref rid="B33" ref-type="bibr">Maya
et al. 2003)</xref>. Despite its notable trypanocidal activity, 9 was not approved for
clinical use due to reports of in vitro mutagenic and genotoxic effects associated with the
reduction of the nitro group (<xref rid="B21" ref-type="bibr">Ferreira &amp; Ferreira
1986</xref>, <xref rid="B42" ref-type="bibr">Poli et al. 2002</xref>, <xref rid="B37" ref-type="bibr">Nesslany et al. 2004</xref>), but the nature of the mutagenic
metabolite was not yet characterised.</p><p>
<fig id="f02" orientation="portrait" position="float"><label>Fig. 2</label><caption><title>: chemical structures of the nitroimidazoles: benznidazole (8), megazol (9)
and a metronidazole analog (10).</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="0074-0276-mioc-110-4-0492-gf02.jpg"/></fig>
</p><p>Several nitroimidazoles possess good oral therapeutic activity against protozoal parasites;
however, concerns over toxicity, mutagenicity and genotoxicity have made drug development
problematic. These adverse properties appear to be related to DNA damage by the products of
the bio-reduction of the nitro group. In fact, positive Ames tests were observed for 1 and
8 using <italic toggle="yes">Salmonella typhimurium</italic> (Rosenkranz Jr et al. 1976). Despite these
results, nitroimidazoles are employed for the clinical treatment of bacterial and protozoal
infections and 1 was included the World Health Organization list of Essential Medicines, a
list of the arsenal of key antimicrobial drugs (<xref rid="B57" ref-type="bibr">WHO
2011</xref>).</p><p>Studies of the mutagenicity have shown that there are differences in the ability of
mammalian cells, bacteria and protozoa to reduce nitroimidazoles (<xref rid="B36" ref-type="bibr">Moreth et al. 2010</xref>). However, to date, there are no conclusive results
from analogous studies of mutagenicity performed in vitro in animals or in humans (<xref rid="B41" ref-type="bibr">Paula et al. 2009</xref>). <xref rid="B54" ref-type="bibr">Voogd et al. (1979)</xref> described the influences of different substituent groups in
the nitroimidazole ring on the redox system, while <xref rid="B56" ref-type="bibr">Walsh et
al. (1987)</xref> group demonstrated that the mutagenic action of 1 is affected by
different substituents at position 1 of the imidazole nucleus. For example, compound 10
(<xref rid="f02" ref-type="fig">Fig. 2</xref>), which is a position structural analogue
of 1, maintained its biological activity without toxic effects. Although some hypotheses
exist, active research in this area has yet to produce a comprehensive mechanism to explain
the toxic and therapeutic activities of these compounds. Thus, further studies to elucidate
the relationship between the biological activity, genotoxicity and mutagenicity of
nitroimidazoles are needed.</p><p>Our group has investigated new nitroimidazoles as trypanocidal agents and their
mutagenic/genotoxic activities. We have observed that these activities do not only depend
on the nitro group (<xref rid="B7" ref-type="bibr">Boechat et al. 2001</xref>, <xref rid="B14" ref-type="bibr">Carvalho et al. 2004</xref>, <xref rid="B11" ref-type="bibr">2006</xref>, <xref rid="B12" ref-type="bibr">2007</xref>, <xref rid="B15" ref-type="bibr">2008</xref>, <xref rid="B13" ref-type="bibr">2014</xref>, <xref rid="B34" ref-type="bibr">Mello et al. 2013</xref>). Encouraged by this observation, in
the present work we evaluated the genotoxic, mutagenic and antitrypanocidal activities of
nine nitroimidazoles (11-19) (<xref rid="f03" ref-type="fig">Fig. 3</xref>). The following
key structural aspects of the nitroimidazoles were examined: the importance of the position
of the nitro group in the imidazole nucleus (C-4 or C-5), the incorporation of an
oxidisable group at N-1 of the nitroimidazole ring, as an anion receptor group and the
importance of the methyl group at C-2. This study may serve as a guide to the search for
new lead compounds for the chemotherapy of human trypanosomiasis and may also identify
safer compounds that may serve as the basis for investigation into the mutagenic activity
of nitroimidazoles.</p><p>
<fig id="f03" orientation="portrait" position="float"><label>Fig. 3</label><caption><title>: chemical structures of the studied nitroimidazoles 11-19.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="0074-0276-mioc-110-4-0492-gf03.jpg"/></fig>
</p><p>Although the focus of this work is studying the genotoxic and mutagenic effects of
different nitroimidazole moieties, the synthesised compounds (11-19) were also assayed
against <italic toggle="yes">T. cruzi</italic>, even though they do not possess the structural
requirements required for trypanocidal activity, i.e., two aromatic and/or heteroaromatic
rings.</p><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><p>
<italic toggle="yes">Chemistry</italic> - 4 or 5-nitroimidazoles with different substituents at the 2
position (11-19) were synthesised following the method described by <xref rid="B47" ref-type="bibr">Skupin et al. (1997)</xref>. Stock solutions of the
compounds were prepared in dimethyl sulfoxide (DMSO) and in all subsequent assays
control sets with the highest required solvent concentrations (5%) were included.</p><p>
<italic toggle="yes">In vitro trypanocidal assay</italic> - Bloodstream trypomastigotes <italic toggle="yes">of T.
cruzi</italic> were obtained from mice intraperitoneally inoculated with the Y strain
of <italic toggle="yes">T. cruzi</italic> and were resuspended in Dulbecco&#8217;s modified Eagle&#8217;s medium
plus 10% foetal calf serum at a concentration of 10<sup>7</sup> parasites/mL. This
suspension (100 &#956;L) was added to an equal volume of 11 to 19 and incubated for 24 h at
37&#186;C under a 5% CO<sub>2</sub> atmosphere. Cell counts were then performed using a
Neubauer chamber and the concentration that produced lysis of 50% of the parasites
(IC<sub>50</sub>) was determined. Untreated and BZ-treated parasites were used as
controls (<xref rid="B13" ref-type="bibr">Carvalho et al. 2014</xref>). The experiments
were conducted in accordance with the guidelines established by the Oswaldo Cruz
Foundation Committee of Ethics for the Use of Animals (LW 16-13).</p><p>
<italic toggle="yes">In vitro treatment and cytotoxicity assay in whole blood</italic> - Heparinised
human blood was obtained by venipuncture immediately before the assays. Whole blood was
treated for 2 h at 37&#186;C with different concentrations of 9 (380-4,000 &#181;M) and of 11 to
19 (148-6,400 &#181;M). The cell viability was determined using the fluorescein diacetate
(FDA)/ethidium bromide (EtBr)-assay, in which viable cells are labelled in green, while
dead ones display orange-stained nuclei (<xref rid="B26" ref-type="bibr">Hartmann &amp;
Speit 1997</xref>). Whole blood (50 &#181;L) was mixed with an equal volume of a freshly
prepared staining solution consisting of 30 &#181;g/mL FDA plus 8 &#181;g/mL EtBr in
phosphate-buffered saline (PBS). Samples (50 &#181;L) were spread on a microscope slide,
covered with a coverslip and observed using a fluorescence microscope. Two hundred cells
were analysed for each treatment. This toxicity test was performed to determine the
range of drug concentrations in the subsequent approaches: concentrations that led to
more than 30% loss of viability were excluded (<xref rid="B3" ref-type="bibr">Anderson
et al. 1998</xref>, <xref rid="B27" ref-type="bibr">Henderson et al.
1998</xref>).</p><p>
<italic toggle="yes">In vitro alkaline single cell gel electrophoresis (SCGE) or the comet
assay</italic> - At the end of a 2 h-treatment, DNA damage in the whole blood was
evaluated in duplicate using an alkaline comet assay (<xref rid="B49" ref-type="bibr">Speit &amp; Hartmann 2006</xref>). Methyl methane-sulfonate (MMS) (160 &#181;M) (Aldrich,
USA) was used as a positive control. Aliquots of 5 &#181;L of whole blood were mixed with 120
&#181;L of 0.5% low melting-point agarose (LMPA) (Sigma-Aldrich, USA) in PBS at 37&#186;C and were
applied to microscope slides previously covered with 1.5% normal melting-point agarose
(Sigma-Aldrich). Then, the slides were covered with coverslips and after LMPA
solidification (3 min/4-5&#186;C), the coverslips were removed and the slides were immersed
in cold lysing solution (2.5 M NaCl, 100 mM Na<sub>2</sub>EDTA, 10 mM Tris, 1%
N-lauroylsarcosine sodium salt, 1% Triton X-100, 10% DMSO, pH 10) for at least 1 h at
4-5&#186;C, protected from light. Afterwards, the slides were placed in a horizontal gel
electrophoresis unit (Bio-Rad) filled with a freshly prepared alkaline buffer at a pH
&gt; 13 (300 mM NaOH, 1 mM EDTA). The times for the alkali treatment and the
electrophoresis of the DNA (0.86 V/cm and 300 mA) were 20 min each in an ice bath. The
slides were neutralised by washing three times (5 min) in Tris buffer (0.4 M Tris, pH
7.5), dried, fixed in absolute ethanol (99.8%) for approximately 10 min and left at room
temperature overnight. Then, each slide was covered with 30 &#181;L of EtBr (20 &#181;g/mL) and a
coverslip and analysed using a fluorescence microscope at 400X magnification.</p><p>Fifty random cells per slide (200 cells per treatment) were visually analysed in a
blinded manner according to tail size into four classes of damage: 0 (undamaged, i.e.,
no visible tail), 1 (slightly damaged), 2 (moderately damaged) and 3 (maximally damaged,
i.e., the head of comet was very small and most of the DNA was in the tail) (<xref rid="B29" ref-type="bibr">Kobayashi et al. 1995</xref>). DNA damage was expressed as
arbitrary units (AU) as percentage of cells into each of the four classes according to
the formula AU = (0 x M0) + (1 x M1) + (2 x M2) + (3 x M3).</p><p>The codes M0, M1, M2 and M3 correspond to the number of cells within damage classes 0,
1, 2 and 3, respectively. Thus, the total DNA damage score [total arbitrary units (TAU)]
for 200 comets range from zero (undamaged) to 600 (maximally damaged). The experiments
were performed in triplicate and the statistical significance (p &lt; 0.05) between the
treated and control groups was evaluated using Student&#8217;s one-tailed <italic toggle="yes">t
</italic>test (<xref rid="B29" ref-type="bibr">Kobayashi et al. 1995</xref>, <xref rid="B38" ref-type="bibr">OECD iLibrary 1997</xref>)
</p><p>
<italic toggle="yes">Salmonella/Microsome mutagenicity test</italic> - Four samples with nitro group
at positions 4 (16 and 17) and 5 (13 and 18) and different substituent groups at
position N-1 were selected for this analysis (<xref rid="f03" ref-type="fig">Fig.
3</xref>). The <italic toggle="yes">Salmonella</italic>/Microsome mutagenicity test evaluates
mutations in the DNA of genetically modified <italic toggle="yes">Salmonella enterica</italic>
serovar <italic toggle="yes">Typhimurium</italic> strains that lack the ability to synthesise
histidine (<italic toggle="yes">His</italic>
<sup>-</sup>). The strains TA97, TA98, TA100, TA102 and TA1535 were utilised following
the guidelines for the testing of chemicals (<xref rid="B32" ref-type="bibr">Maron &amp;
Ames 1983</xref>). At least five strains of bacteria were used, including four
strains of <italic toggle="yes">S. enterica</italic> serovar <italic toggle="yes">typhimurium</italic> (TA1535;
TA1537 or TA97a or TA97; TA98 and TA100).</p><p>A volume of 100 &#181;L of the nitroimidazole (25-2,500 &#181;M), 500 &#181;L of PBS and 100 &#181;L of the
bacterial suspension (2 x 10<sup>9</sup> cells/mL) were combined in a test tube. Next, 2
mL of top agar (7 g/L agar; 5 g/L NaCl; 0.0105 g/L L-histidine; 0.0122 g/L biotin; pH
7.4, 45&#186;C) was added and the mixture was poured into a Petri dish containing minimal
agar {15 g/L agar, Vogel-Bonner E medium 10X [10 g/L MgSO<sub>4</sub>.7H<sub>2</sub>O;
100 g/L C<sub>6</sub>H<sub>8</sub>O<sub>7</sub>.H<sub>2</sub>O; 500 g/L
K<sub>2</sub>HPO<sub>4</sub>; 175 g/L
Na(NH<sub>4</sub>)HPO<sub>4</sub>.4H<sub>2</sub>O]} with 20 g/L glucose. The plates
were incubated at 37&#186;C for 72 h and the <italic toggle="yes">His</italic>
<sup><italic toggle="yes">+ </italic></sup> revertant colonies were counted. The positive controls
included 1.0 &#181;g/plate 4-nitroquinoline-N-oxide (4-NQO) for TA97 and TA98, 0.5 &#181;g/plate
sodium azide for TA100 and TA1535 and 0.5 &#181;g/plate mitomycin C for TA102. All of the
chemicals were obtained from Sigma Co (USA). DMSO was used as the negative control. The
sample was considered positive for mutagenicity when the following conditions were
observed: the number of revertant colonies in the assay was at least twice the number of
spontaneous revertants [mutagenicity index (MI) &#8805; 2], a significant response to the
analysis of variance (p &#8804; 0.05) was observed and a reproducible, positive dose-response
curve (p &#8804; 0.01) was obtained. The MI was calculated by dividing the number of
<italic toggle="yes">His</italic><sup><italic toggle="yes">+</italic></sup> colonies induced in the sample by
the number of <italic toggle="yes">His</italic><sup><italic toggle="yes">+</italic></sup> colonies in the negative
control. All the experiments were performed in triplicate and were repeated twice.
Statistical significance was evaluated using analysis of variance, including a one-way
ANOVA and Tukey&#8217;s honestly significant difference HSD <italic toggle="yes">post hoc</italic> analysis
(p &#8804; 0.01). The mutagenic potency slope was obtained using the Bernstein model (<xref rid="B5" ref-type="bibr">Bernstein et al. 1982</xref>).</p><p>
<italic toggle="yes">Survival experiments</italic> - Quantitative evaluations were performed to
determine the cytotoxic effects of the nitroimidazoles by the Ames test. Ten microlitres
of each treated bacterial suspension (10<sup>8</sup> cells/mL) was diluted in a saline
solution (NaCl, 9 g/L-0.9%). Then, 100 &#181;L of the solution was placed on a Petri dish
containing nutrient agar [0.8% bacto nutrient broth (Difco), 0.5% NaCl and 1.5% agar]
and incubated at 37&#186;C for 24 h. The colonies were counted and the survival percentage
was determined with respect to the negative control. All the experiments were performed
in triplicate and were repeated twice (<xref rid="B1" ref-type="bibr">Aiub et al.
2004</xref>).</p></sec><sec sec-type="results"><title>RESULTS</title><p>The present study focused on the use of SCGE to evaluate DNA damage induced by the
nitroimidazoles 11-19 with the objective of mapping genotoxic activity, as displayed in
<xref rid="t1" ref-type="table">Table I</xref>. The treatment of blood cells with 9
over the range of 380-4,000 &#181;M for 2 h at 37&#176;C did not reduce the cell viability.
However, a highly significant (p &lt; 0.01) genotoxic effect was observed at
concentrations higher than of 1,562 &#181;M. The positive control, MMS, was highly active at
160 &#181;M (p &lt; 0.0001), causing a clear genotoxic effect with a TAU value of 454.3 &#177;
9.2. In the range of 148-6,400 &#181;M, the nitroimidazoles 11, 12, 16 and 18 did not alter
cellular viability and caused no DNA damage compared to the control group (p &gt; 0.05).
On the other hand, at the same concentrations, 13, 15 and 19 caused moderate alterations
to the DNA, whereas 14, 17 and 9 caused strong alterations of the DNA structure.</p><p>
<table-wrap id="t1" orientation="portrait" position="float"><label>TABLE I</label><caption><title>Anti-<italic toggle="yes">Trypanosoma cruzi</italic> and genotoxic in vitro activities
of nitroimidazoles 11-19</title></caption><table frame="hsides" rules="groups"><colgroup width="33%" span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th style="font-weight:normal" align="left" rowspan="1" colspan="1">Compound</th><th style="font-weight:normal" rowspan="1" colspan="1">IC<sub>50</sub>/24 h
(&#181;M)</th><th style="font-weight:normal" rowspan="1" colspan="1">Genotoxic</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">9.9 &#177; 0.8</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">1,690.9 &#177; 371.8</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">1,147.3 &#177; 111.6</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">1,749.7 &#177; 184.6</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">1,170.7 &#177; 100.5</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">1,585.8 &#177; 218.3</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">1,132.4 &#177; 86.3</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">1,049.4 &#177; 63.7</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">&gt; 2,000</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">902.6 &#177; 83.4</td><td align="center" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>0: undamaged; 1: slightly damaged; 2: moderately damaged; 3: maximally
damaged (see Materials and Methods for more details).</p></fn></table-wrap-foot></table-wrap>
</p><p>The nitroimidazoles were also assayed against <italic toggle="yes">T. cruzi</italic>. Compounds 11-17
and 19 exhibited an IC<sub>50</sub> in the range of 902-1,749 &#181;M, whereas for 18, this
parameter was &gt; 2000 &#181;M. Under the same experimental conditions, the values for 8 and
9 were 9.7 &#177; 2.4 and 9.9 &#177; 0.8 &#181;M, respectively (<xref rid="t1" ref-type="table">Table
I</xref>). As expected, the compounds were not active trypanocides because they do
not possess the structural requirements required for trypanocidal activity, i.e., two
aromatic and/or heteroaromatic rings.</p><p>
<xref rid="f04" ref-type="fig">Fig. 4</xref> illustrates the mutagenicity and
cytotoxicity induced by nitroimidazoles 13, 16, 17 and 18 using <italic toggle="yes">S.
typhimurium</italic> strains TA97, TA98, TA100, TA102 and TA1535. At concentrations
between 25-2,500 &#181;M, these compounds did not induce frameshift mutations in TA97.
However, compounds 17 and 18 were capable of inducing frameshift mutations in TA98,
whereas 18 also induced transversions and transitions in TA102 and base pair
substitutions in TA1535. Furthermore, all of the nitroimidazoles were capable of
inducing dose-dependent base pair substitutions for at least two tested doses in TA100,
the most mutagen-responsive strain (<xref rid="f05" ref-type="fig">Fig. 5</xref>). In
addition, cytotoxic activity was present only in the higher concentration (2,500 &#181;M) for
at least one sample and strain. Using the Bernstein correlation, the number of revertant
colonies per &#181;g (rev/&#181;g) was deduced. In addition, higher mutagenic potency correlated
with an increased risk of being a mutagen.</p><p>
<fig id="f04" orientation="portrait" position="float"><label>Fig. 4</label><caption><title>: <italic toggle="yes">Salmonella</italic>/Microsome assay of the nitroimidazoles 13,
16, 17 and 18. rev/mM: revertant colonies per nM.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="0074-0276-mioc-110-4-0492-gf04.jpg"/></fig>
</p><p>
<fig id="f05" orientation="portrait" position="float"><label>Fig. 5</label><caption><title>: genotoxic (comet assay) and mutagenic
(<italic toggle="yes">Salmonella</italic>/Microsome assay) response of the nitroimidazoles
13, 16, 17 and 18.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="0074-0276-mioc-110-4-0492-gf05.jpg"/></fig>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Although nitroimidazoles have been clinically used for chemotherapy against several
parasites, the mechanisms underlying their genotoxic and biological activities are not
fully understood. On the basis of the high activity of 9 against trypanosomatids (<xref rid="B23" ref-type="bibr">Filardi &amp; Brener 1982</xref>, <xref rid="B19" ref-type="bibr">Enanga et al. 1998</xref>, <xref rid="B17" ref-type="bibr">Darsaud et al.
2004</xref>) together with the success of NFX-eflornithine for the treatment of HAT
(<xref rid="B61" ref-type="bibr">Yun et al. 2010</xref>), the Drugs for Neglected
Diseases initiative triggered a systematic review of more than 700 nitroheterocycles
(mostly nitroimidazoles) (<xref rid="B50" ref-type="bibr">Torreele et al. 2010</xref>).
In this context, fexinidazole (5-nitroimidazole), first described in 1978 by <xref rid="B59" ref-type="bibr">Winkelmann and Raether (1978)</xref>, emerged as a
potential candidate. The development of this compound was previously abandoned largely
due to the prejudice against nitroaromatic compounds (<xref rid="B39" ref-type="bibr">Patterson &amp; Wyllie 2014</xref>). More recently, analysis of pharmacological and
toxicological profiles suggested that fexinidazole is a promising candidate for both HAT
(<xref rid="B50" ref-type="bibr">Torreele et al. 2010</xref>) and Chagas disease
(<xref rid="B4" ref-type="bibr">Bahia et al. 2012</xref>). These facts and our
previous results prompted us to re-evaluate the role of the nitro group in the toxic
effects of nitroimidazoles. The presence of a nitro group in a compound can result in
several toxicity issues, including genotoxicity and mutagenicity (<xref rid="B55" ref-type="bibr">Walsh &amp; Miwa 2011</xref>). However, at the same time, this functional
group is necessary for the desired biological activity. Consequently, nitrocompounds are
not included in screening libraries due to this unwanted functionality (<xref rid="B9" ref-type="bibr">Brenk et al. 2008</xref>) and are not synthesised in
medicinal chemistry programs [reviewed in <xref rid="B39" ref-type="bibr">Patterson and
Wyllie (2014)</xref>].</p><p>This work investigated the importance of different functional groups of C-4 or C-5
nitroimidazoles having oxidisable groups bonded at N-1 on the biological and mutagenic
activities of the compounds.</p><p>The results of the genotoxicity assays are described in <xref rid="t1" ref-type="table">Table I</xref>. Nitroimidazoles 11 and 12, which contain a NO<sub>2</sub> group at
C-4 and a CH<sub>3</sub> group at C-2, were not genotoxic compared to 13, 14 and 15,
which possess a NO<sub>2</sub> group at C-5 and exhibited moderate to high genotoxicity.
Nitroimidazole 13 had moderate mutagenic effects. We also observed a comparable result
between 11 (2-CH<sub>3</sub> and 4-NO<sub>2</sub>), which was not genotoxic and its
analogue 4 (2-CH<sub>3</sub> and 5-NO<sub>2</sub>), which is known to be a mutagenic
agent (<xref rid="B22" ref-type="bibr">Ferreiro et al. 2002</xref>). However, when the
nitroimidazole had no CH<sub>3 </sub>group at C-2, the position of the NO<sub>2</sub>
group had no influence on genotoxic activity. This is the case for 16 (4-NO<sub>2</sub>)
and 18 (5-NO<sub>2</sub>), which exhibited behaviours similar to that of 11 and 12 (no
genotoxicity). When comparing pairs of similar compounds, for instance, 16
(4-NO<sub>2</sub> and N-CH<sub>2</sub>OAcCH<sub>2</sub>Cl) with 17 (4-NO<sub>2</sub>
and N-CH<sub>2</sub>OAcCH<sub>2</sub>F) and 14 (2-CH<sub>3</sub>; 5-NO<sub>2</sub>;
N-CH<sub>2</sub>OHCH<sub>2</sub>F) with 15 (2-CH<sub>3</sub>; 5-NO<sub>2</sub>;
N-CH<sub>2</sub>OHCH<sub>2</sub>OH), we observed that the presence of fluorine
induced genotoxicity. The fluorinated compounds 14 and 17 showed higher genotoxicity
regardless of the presence of CH<sub>3</sub> at C-2 or NO<sub>2</sub> at C-4 or C-5.
However, when comparing compounds 11 (2-CH<sub>3</sub>; 4-NO<sub>2</sub>;
N-CH<sub>2</sub>OHCH<sub>2</sub>Cl) and 12 (2-CH<sub>3</sub>; 4-NO<sub>2</sub>;
N-CH<sub>2</sub>OHCH<sub>2</sub>F), the fluorine atom had no influence on
genotoxicity.</p><p>Four compounds were selected for the Ames assays [nitro group at positions 4 (16 and 17)
and 5 (13 and 18) and different substituent groups at position N-1] with the aim of
clarifying whether the increase in mutagenicity of nitroimidazoles was dependent only on
the position of the nitro group or was related to the presence of more or less reactive
halogens.</p><p>The results of the cytotoxicity and mutagenicity analyses are described in <xref rid="f04" ref-type="fig">Fig. 4</xref> and <xref rid="t2" ref-type="table">Table
II</xref>. The four <italic toggle="yes">S. typhimurium</italic> strains have GC base pairs at the
primary reversion site and as a result, it is known that these strains may not detect
certain oxidising mutagens, cross-linking agents and hydrazines. Such substances may be
detected by <italic toggle="yes">S. typhimurium</italic> TA102, which has an AT base pair at the
primary reversion site (<xref rid="B38" ref-type="bibr">OECD iLibrary 1997</xref>). The
data showed that 17 is a highly potent mutagen (41.7 rev/&#181;g to TA100), whereas 13, 16
and 18 are low-potency mutagens, causing approximately 8-9 rev/&#181;g. The data in <xref rid="f05" ref-type="fig">Fig. 5</xref> further corroborate this finding, on the basis
that the number of TAU in the comet assay is high for 17, similar to the number of
rev/&#181;g.</p><p>
<table-wrap id="t2" orientation="portrait" position="float"><label>TABLE II</label><caption><title>Genotoxicity, mutagenicity and mutagenic potency slope of nitroimidazoles
13, 16, 17 and 18</title></caption><table frame="hsides" rules="groups"><colgroup width="10%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="2" style="font-weight:normal" align="left" colspan="1">Compound</th><th style="font-weight:normal" rowspan="1" colspan="1">Genotoxicity</th><th colspan="3" style="font-weight:normal" rowspan="1">Ames test (MI &gt; 2)
- Mutagenicity</th><th colspan="5" style="font-weight:normal" rowspan="1">Mutagenic potency
slope (revertants/&#181;g)</th></tr><tr><th style="font-weight:normal" rowspan="1" colspan="1">1,562 &#181;M</th><th style="font-weight:normal" rowspan="1" colspan="1">250 &#181;M</th><th style="font-weight:normal" rowspan="1" colspan="1">1,250 &#181;M</th><th style="font-weight:normal" rowspan="1" colspan="1">2,500 &#181;M</th><th style="font-weight:normal" rowspan="1" colspan="1">TA97</th><th style="font-weight:normal" rowspan="1" colspan="1">TA98</th><th style="font-weight:normal" rowspan="1" colspan="1">TA100</th><th style="font-weight:normal" rowspan="1" colspan="1">TA102</th><th style="font-weight:normal" rowspan="1" colspan="1">TA1535</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">1 (300 TAU)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">TA100</td><td align="center" rowspan="1" colspan="1">TA100</td><td align="center" rowspan="1" colspan="1">0.30 &#177; 0.22</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">8.98 &#177; 0.71</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">0 (10 TAU)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">TA100</td><td align="center" rowspan="1" colspan="1">TA100</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">6.60 &#177; 0.63</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">3 (411 TAU)</td><td align="center" rowspan="1" colspan="1">TA100</td><td align="center" rowspan="1" colspan="1">TA100</td><td align="center" rowspan="1" colspan="1">TA98, TA100</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">0.55 &#177; 0.08</td><td align="center" rowspan="1" colspan="1">41.70 &#177; 3.71</td><td align="center" rowspan="1" colspan="1">2.51 &#177; 0.44</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">0 (32 TAU)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">TA100</td><td align="center" rowspan="1" colspan="1">TA98, TA100, TA102, TA1535</td><td align="center" rowspan="1" colspan="1">2.13 &#177; 0.14</td><td align="center" rowspan="1" colspan="1">0.69 &#177; 0.05</td><td align="center" rowspan="1" colspan="1">8.18 &#177; 0.15</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">0.51 &#177; 0.07</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>MI: mutagenicity inde; NA: not applicable; TAU: total arbitrary units for
the positive control, methyl methane-sulfonate value was 454.3 &#177; 9.2.</p></fn></table-wrap-foot></table-wrap>
</p><p>In conclusion, we observed that the type and position of different substituents bonded
to the imidazole ring have a significant influence on the toxicological activity.
Whereas nitroimidazoles 11 and 12 were not genotoxic, nitroimidazoles 13, 15 and 19 were
moderately genotoxic and mutagenic. Nitroimidazole 16 was neither genotoxic nor
mutagenic and 18 was moderately mutagenic but not genotoxic. These results demonstrate
that the nitro group is not solely responsible for the mutagenic or genotoxic
activity.</p><p>Furthermore, the data suggest that the nitroimidazole may be the moiety most likely to
be responsible for the genotoxic and mutagenic effects, but in the analogues tested,
this moiety was unable to provide anti-<italic toggle="yes">T. cruzi</italic> activity.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p>Financial support: FAPERJ, CNPq, FIOCRUZ, Organisch-Chemisches Institut,
Westf&#228;lischen Wilhelms-Universit&#228;t M&#252;nster</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B1"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aiub</surname><given-names>CAF</given-names></name><name name-style="western"><surname>Stankevicins</surname><given-names>L</given-names></name><name name-style="western"><surname>Costa</surname><given-names>V</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>F</given-names></name><name name-style="western"><surname>Mazzei</surname><given-names>JL</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>AS</given-names></name><name name-style="western"><surname>Moura</surname><given-names>RS</given-names></name><name name-style="western"><surname>Felzenszwalb</surname><given-names>I</given-names></name></person-group><year>2004</year><article-title>Genotoxic evaluation of a vinifera skin extract that
present pharmacological activities</article-title><source>Food Chem Toxicol</source><volume>42</volume><fpage>969</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">15110106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fct.2004.02.009</pub-id></element-citation></ref><ref id="B2"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Soud</surname><given-names>YA</given-names></name><name name-style="western"><surname>Al-Masoudi</surname><given-names>NA</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>HG</given-names></name><name name-style="western"><surname>Clercq</surname><given-names>E</given-names></name><name name-style="western"><surname>Pannecouque</surname><given-names>C</given-names></name></person-group><year>2007</year><article-title>Nitroimidazoles. V. Synthesis and anti-HIV evaluation of
new 5-substituted piperazinyl-4-nitroimidazole derivatives</article-title><source>Acta Pharm</source><volume>57</volume><fpage>379</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">18165184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2478/v10007-007-0031-7</pub-id></element-citation></ref><ref id="B3"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>D</given-names></name><name name-style="western"><surname>Yu</surname><given-names>TW</given-names></name><name name-style="western"><surname>Mcgregor</surname><given-names>DB</given-names></name></person-group><year>1998</year><article-title>Comet assay responses as indicators of carcinogen
exposure</article-title><source>Mutagenesis</source><volume>13</volume><fpage>539</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">9862185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/mutage/13.6.539</pub-id></element-citation></ref><ref id="B4"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahia</surname><given-names>MT</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>IM</given-names></name><name name-style="western"><surname>Martins</surname><given-names>TA</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>AF</given-names></name><name name-style="western"><surname>Diniz</surname><given-names>LF</given-names></name><name name-style="western"><surname>Caldas</surname><given-names>IS</given-names></name><name name-style="western"><surname>Talvani</surname><given-names>A</given-names></name><name name-style="western"><surname>Trunz</surname><given-names>BB</given-names></name><name name-style="western"><surname>Torreele</surname><given-names>E</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>I</given-names></name></person-group><year>2012</year><article-title>Fexinidazole: a potential new drug candidate for Chagas
disease</article-title><source>PLoS Negl Trop Dis</source><volume>6</volume><elocation-id/><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0001870</pub-id><pub-id pub-id-type="pmcid">PMC3486905</pub-id><pub-id pub-id-type="pmid">23133682</pub-id></element-citation></ref><ref id="B5"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>L</given-names></name><name name-style="western"><surname>Kaldor</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Pike</surname><given-names>MC</given-names></name></person-group><year>1982</year><article-title>An empirical approach to the statistical analysis of
mutagenesis data from Salmonella test</article-title><source>Mutat Res</source><volume>97</volume><fpage>267</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">6750390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-1161(82)90026-7</pub-id></element-citation></ref><ref id="B6"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boda</surname><given-names>C</given-names></name><name name-style="western"><surname>Enanga</surname><given-names>B</given-names></name><name name-style="western"><surname>Dumet</surname><given-names>H</given-names></name><name name-style="western"><surname>Chauviere</surname><given-names>G</given-names></name><name name-style="western"><surname>Labrousse</surname><given-names>F</given-names></name><name name-style="western"><surname>Couquet</surname><given-names>C</given-names></name><name name-style="western"><surname>Saivin</surname><given-names>S</given-names></name><name name-style="western"><surname>Houin</surname><given-names>G</given-names></name><name name-style="western"><surname>Perie</surname><given-names>J</given-names></name><name name-style="western"><surname>Dumas</surname><given-names>M</given-names></name><name name-style="western"><surname>Bouteille</surname><given-names>B</given-names></name></person-group><year>2004</year><article-title>Plasma kinetics and efficacy of oral megazol treatment
in Trypanosoma brucei brucei-infected sheep</article-title><source>Vet Parasitol</source><volume>121</volume><fpage>213</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">15135860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetpar.2004.02.027</pub-id></element-citation></ref><ref id="B7"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boechat</surname><given-names>N</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>AS</given-names></name><name name-style="western"><surname>Fernandez-Ferreira</surname><given-names>E</given-names></name><name name-style="western"><surname>Soares</surname><given-names>ROA</given-names></name><name name-style="western"><surname>Souza</surname><given-names>AS</given-names></name><name name-style="western"><surname>Gibaldi</surname><given-names>D</given-names></name><name name-style="western"><surname>Bozza</surname><given-names>M</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>AC</given-names></name></person-group><year>2001</year><article-title>Novel nitroimidazoles with trypanocidal and cell growth
inhibition activities</article-title><source>Cytobios</source><volume>105</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">11393774</pub-id></element-citation></ref><ref id="B8"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bone</surname><given-names>W</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>CH</given-names></name><name name-style="western"><surname>Skupin</surname><given-names>R</given-names></name><name name-style="western"><surname>Haufe</surname><given-names>G</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>TG</given-names></name></person-group><year>1997</year><article-title>Toxicity of ornidazole and its analogues on rat
spermatozoa as reflected in motility parameters</article-title><source>Int J Androl</source><volume>20</volume><fpage>347</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">9568527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2605.1998.00077.x</pub-id></element-citation></ref><ref id="B9"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brenk</surname><given-names>R</given-names></name><name name-style="western"><surname>Schipani</surname><given-names>A</given-names></name><name name-style="western"><surname>James</surname><given-names>D</given-names></name><name name-style="western"><surname>Krasowski</surname><given-names>A</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>IH</given-names></name><name name-style="western"><surname>Frearson</surname><given-names>J</given-names></name><name name-style="western"><surname>Wyatt</surname><given-names>PG</given-names></name></person-group><year>2008</year><article-title>Lessons learnt from assembling screening libraries for
drug discovery for neglected diseases</article-title><source>Chem Med Chem</source><volume>3</volume><fpage>435</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">18064617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cmdc.200700139</pub-id><pub-id pub-id-type="pmcid">PMC2628535</pub-id></element-citation></ref><ref id="B10"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buschini</surname><given-names>A</given-names></name><name name-style="western"><surname>Giordani</surname><given-names>F</given-names></name><name name-style="western"><surname>Albuquerque</surname><given-names>CN</given-names></name><name name-style="western"><surname>Pellacani</surname><given-names>C</given-names></name><name name-style="western"><surname>Pelosi</surname><given-names>G</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>C</given-names></name><name name-style="western"><surname>Zucchi</surname><given-names>TMAD</given-names></name><name name-style="western"><surname>Poli</surname><given-names>P</given-names></name></person-group><year>2007</year><article-title>Trypanocidal nitroimidazole derivatives: relationships
among chemical structure and genotoxic activity</article-title><source>Biochem Pharmacol</source><volume>73</volume><fpage>1537</fpage><lpage>1547</lpage><pub-id pub-id-type="pmid">17291457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2007.01.024</pub-id></element-citation></ref><ref id="B11"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>AS</given-names></name><name name-style="western"><surname>Gibaldi</surname><given-names>D</given-names></name><name name-style="western"><surname>Bozza</surname><given-names>M</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>AC</given-names></name><name name-style="western"><surname>Boechat</surname><given-names>N</given-names></name></person-group><year>2006</year><article-title>Synthesis and trypanocidal evaluation of news
5-[N-(3-(5-substituted)-1,3,4-thiadiazolyl)]amino-1-methyl-4-nitroimidazoles</article-title><source>Lett Drug Des Discov</source><volume>3</volume><fpage>98</fpage><lpage>101</lpage></element-citation></ref><ref id="B12"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>AS</given-names></name><name name-style="western"><surname>Menna-Barreto</surname><given-names>RFS</given-names></name><name name-style="western"><surname>Romeiro</surname><given-names>NC</given-names></name><name name-style="western"><surname>Castro</surname><given-names>S</given-names></name><name name-style="western"><surname>Boechat</surname><given-names>N</given-names></name></person-group><year>2007</year><article-title>Design, synthesis and activity against Trypanosoma cruzi
of azaheterocyclic analogs of megazol</article-title><source>Med Chem Res</source><volume>3</volume><fpage>460</fpage><lpage>465</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/157340607781745519</pub-id><pub-id pub-id-type="pmid">17897071</pub-id></element-citation></ref><ref id="B13"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>AS</given-names></name><name name-style="western"><surname>Salom&#227;o</surname><given-names>K</given-names></name><name name-style="western"><surname>Castro</surname><given-names>SL</given-names></name><name name-style="western"><surname>Conde</surname><given-names>TR</given-names></name><name name-style="western"><surname>Zamith</surname><given-names>HPS</given-names></name><name name-style="western"><surname>Caffarena</surname><given-names>ER</given-names></name><name name-style="western"><surname>Hall</surname><given-names>BS</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>SR</given-names></name><name name-style="western"><surname>Boechat</surname><given-names>N</given-names></name></person-group><year>2014</year><article-title>Megazol and its bioisostere 4H-1,2,4-triazole: comparing
the trypanocidal, cytotoxic and genotoxic activities and their in vitro and in
silico interactions with the Trypanosoma brucei nitroreductase
enzyme</article-title><source>Mem Inst Oswaldo Cruz</source><volume>109</volume><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">24676659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/0074-0276140497</pub-id><pub-id pub-id-type="pmcid">PMC4131783</pub-id></element-citation></ref><ref id="B14"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>SA</given-names></name><name name-style="western"><surname>Silva</surname><given-names>EF</given-names></name><name name-style="western"><surname>Santa-Rita</surname><given-names>RM</given-names></name><name name-style="western"><surname>Castro</surname><given-names>SL</given-names></name><name name-style="western"><surname>Fraga</surname><given-names>CAM</given-names></name></person-group><year>2004</year><article-title>Synthesis and antitrypanosomal profile of new
functionalyzed 1,3,4-thiadiazole-2-arylhydrazone derivatives, designed as
non-mutagenic megazol analogues</article-title><source>Bioorg Med Chem Lett</source><volume>14</volume><fpage>5967</fpage><lpage>5970</lpage><pub-id pub-id-type="pmid">15546709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmcl.2004.10.007</pub-id></element-citation></ref><ref id="B15"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>SA</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>FAS</given-names></name><name name-style="western"><surname>Salom&#227;o</surname><given-names>K</given-names></name><name name-style="western"><surname>Romeiro</surname><given-names>NC</given-names></name><name name-style="western"><surname>Wardell</surname><given-names>SMVS</given-names></name><name name-style="western"><surname>Castro</surname><given-names>SL</given-names></name><name name-style="western"><surname>Silva</surname><given-names>EF</given-names></name><name name-style="western"><surname>Fraga</surname><given-names>CAM</given-names></name></person-group><year>2008</year><article-title>Studies toward the structural optimization of new
brazilizone-related trypanocidal 1,3,4-thiadiazole-2-arylhydrazone
derivatives</article-title><source>Bioorg Med Chem</source><volume>16</volume><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">17904851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmc.2007.09.027</pub-id></element-citation></ref><ref id="B16"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>TG</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>CH</given-names></name><name name-style="western"><surname>Skupin</surname><given-names>R</given-names></name><name name-style="western"><surname>Haufe</surname><given-names>G</given-names></name></person-group><year>1997</year><article-title>The antifertility potential of ornidazole analogues in
rats</article-title><source>J Androl</source><volume>18</volume><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">9283957</pub-id></element-citation></ref><ref id="B17"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darsaud</surname><given-names>A</given-names></name><name name-style="western"><surname>Chevrier</surname><given-names>C</given-names></name><name name-style="western"><surname>Bourdon</surname><given-names>L</given-names></name><name name-style="western"><surname>Dumas</surname><given-names>M</given-names></name><name name-style="western"><surname>Buguet</surname><given-names>A</given-names></name><name name-style="western"><surname>Bouteille</surname><given-names>B</given-names></name></person-group><year>2004</year><article-title>Megazol combined with suramin improves a new diagnosis
index of the early meningo-encephalitic phase of experimental African
trypanosomiasis</article-title><source>Trop Med Health</source><volume>9</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-3156.2003.01154.x</pub-id><pub-id pub-id-type="pmid">14728611</pub-id></element-citation></ref><ref id="B18"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castro</surname><given-names>SL</given-names></name><name name-style="western"><surname>Meirelles</surname><given-names>MNL</given-names></name></person-group><year>1986</year><article-title>Effect of drugs on Trypanosoma cruzi and on its
interaction with heart muscle cell in vitro</article-title><source>Mem Inst Oswaldo Cruz</source><volume>82</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">3333533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/s0074-02761987000200009</pub-id></element-citation></ref><ref id="B19"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enanga</surname><given-names>B</given-names></name><name name-style="western"><surname>Keita</surname><given-names>M</given-names></name><name name-style="western"><surname>Chauvi&#232;re</surname><given-names>G</given-names></name><name name-style="western"><surname>Dumas</surname><given-names>M</given-names></name><name name-style="western"><surname>Bouteille</surname><given-names>B</given-names></name></person-group><year>1998</year><article-title>Megazol combined with suramin: a chemotherapy regimen
which reversed the CNS pathology in a model of human African trypanosomiasis in
mice</article-title><source>Trop Med Int Health</source><volume>3</volume><fpage>736</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">9754669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-3156.1998.00291.x</pub-id></element-citation></ref><ref id="B20"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enanga</surname><given-names>B</given-names></name><name name-style="western"><surname>Ndong</surname><given-names>JMM</given-names></name><name name-style="western"><surname>Boudra</surname><given-names>H</given-names></name><name name-style="western"><surname>Debrauwer</surname><given-names>L</given-names></name><name name-style="western"><surname>Dubreuil</surname><given-names>G</given-names></name><name name-style="western"><surname>Bouteille</surname><given-names>B</given-names></name><name name-style="western"><surname>Chauviere</surname><given-names>G</given-names></name><name name-style="western"><surname>Labat</surname><given-names>C</given-names></name><name name-style="western"><surname>Dumas</surname><given-names>M</given-names></name><name name-style="western"><surname>Perie</surname><given-names>J</given-names></name><name name-style="western"><surname>Houin</surname><given-names>G</given-names></name></person-group><year>2000</year><article-title>Pharmacokinetics, metabolism and excretion of megazol in
a Trypanosoma brucei gambiense primate model of human African trypanosomiasis:
preliminary study</article-title><source>Arzneimittelforschung</source><volume>50</volume><fpage>158</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">10719620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0031-1300182</pub-id></element-citation></ref><ref id="B21"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>RC</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>LC</given-names></name></person-group><year>1986</year><article-title>Mutagenicity of CL 64855, a potent anti-Trypanosoma
cruzi drug</article-title><source>Mutat Res</source><volume>171</volume><fpage>11</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">3523230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-1218(86)90003-0</pub-id></element-citation></ref><ref id="B22"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreiro</surname><given-names>GR</given-names></name><name name-style="western"><surname>Bad&#237;as</surname><given-names>LC</given-names></name><name name-style="western"><surname>Lopez-Nigro</surname><given-names>M</given-names></name><name name-style="western"><surname>Palermo</surname><given-names>A</given-names></name><name name-style="western"><surname>Mudry</surname><given-names>M</given-names></name><name name-style="western"><surname>Elio</surname><given-names>PG</given-names></name><name name-style="western"><surname>Carballo</surname><given-names>MA</given-names></name></person-group><year>2002</year><article-title>DNA single strand breaks in peripheral blood lymphocytes
induced by three nitroimidazole derivatives</article-title><source>Toxicol Lett</source><volume>132</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">12044544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-4274(02)00039-5</pub-id></element-citation></ref><ref id="B23"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filardi</surname><given-names>LS</given-names></name><name name-style="western"><surname>Brener</surname><given-names>ZA</given-names></name></person-group><year>1982</year><article-title>Nitroimidazole-thiadiazole derivative with curative
action in experimental Trypanosoma cruzi infections</article-title><source>Ann Trop Med Parasitol</source><volume>76</volume><fpage>293</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">6812514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00034983.1982.11687544</pub-id></element-citation></ref><ref id="B24"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fran&#231;a</surname><given-names>RRF</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>AS</given-names></name><name name-style="western"><surname>Branco</surname><given-names>FSC</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>AC</given-names></name><name name-style="western"><surname>Boechat</surname><given-names>N</given-names></name></person-group><year>2014</year><article-title xml:lang="pt">Inibidores potentes da enzima esterol 14&#945;-desmetilase
contra Trypanosoma cruzi</article-title><source>Rev Virtual Quim</source><volume>6</volume><fpage>1483</fpage><lpage>1516</lpage></element-citation></ref><ref id="B25"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gascon</surname><given-names>J</given-names></name><name name-style="western"><surname>Bern</surname><given-names>C</given-names></name><name name-style="western"><surname>Pinazo</surname><given-names>MJ</given-names></name></person-group><year>2010</year><article-title>Chagas disease in Spain, the United States and other
non-endemic countries</article-title><source>Acta Trop</source><volume>115</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">19646412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actatropica.2009.07.019</pub-id></element-citation></ref><ref id="B26"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Speit</surname><given-names>G</given-names></name></person-group><year>1997</year><article-title>The contribution of cytotoxicity to DNA - effects in the
single cell gel test (comet assay)</article-title><source>Toxicol Lett</source><volume>90</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">9067486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-4274(96)03847-7</pub-id></element-citation></ref><ref id="B27"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>L</given-names></name><name name-style="western"><surname>Wolfreys</surname><given-names>A</given-names></name><name name-style="western"><surname>Fedyk</surname><given-names>J</given-names></name><name name-style="western"><surname>Bourner</surname><given-names>C</given-names></name><name name-style="western"><surname>Windebank</surname><given-names>S</given-names></name></person-group><year>1998</year><article-title>The ability of the comet assay to discriminate between
genotoxins and cytotoxins</article-title><source>Mutagenesis</source><volume>13</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">9491401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/mutage/13.1.89</pub-id></element-citation></ref><ref id="B28"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khabnadideh</surname><given-names>S</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>Z</given-names></name><name name-style="western"><surname>Khalafi-Nezhad</surname><given-names>A</given-names></name><name name-style="western"><surname>Pakshir</surname><given-names>K</given-names></name><name name-style="western"><surname>Heiran</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Shobeiri</surname><given-names>H</given-names></name></person-group><year>2009</year><article-title>Design and synthesis of 2-methyl and 2-methyl-4-nitro
imidazole derivatives as antifungal agents</article-title><source>Iranian J Pharm Sci</source><volume>5</volume><fpage>31</fpage><lpage>36</lpage></element-citation></ref><ref id="B29"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>C</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Sofuni</surname><given-names>T</given-names></name></person-group><year>1995</year><article-title>A comparison between manual microscopic analysis and
computerized image analysis in the single cell gel electrophoresis
assay</article-title><source>MMS Commun</source><volume>3</volume><fpage>103</fpage><lpage>115</lpage></element-citation></ref><ref id="B30"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lages-Silva</surname><given-names>E</given-names></name><name name-style="western"><surname>Filardi</surname><given-names>LS</given-names></name><name name-style="western"><surname>Brener</surname><given-names>Z</given-names></name></person-group><year>1990</year><article-title>Effect of the host specific treatment in the
phagocytosis of Trypanosoma cruzi blood forms by mouse peritoneal
macrophages</article-title><source>Mem Inst Oswaldo Cruz</source><volume>85</volume><fpage>401</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">2152191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/s0074-02761990000400003</pub-id></element-citation></ref><ref id="B31"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Yun</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>YS</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S</given-names></name><name name-style="western"><surname>Oh</surname><given-names>T</given-names></name><name name-style="western"><surname>Kim</surname><given-names>P</given-names></name></person-group><year>2011</year><article-title>Synthesis and antitubercular activity of monocyclic
nitroimidazoles: insights from econazole</article-title><source>Bioorg Med Chem Lett</source><volume>21</volume><fpage>1515</fpage><lpage>1518</lpage><pub-id pub-id-type="pmid">21277200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmcl.2010.12.128</pub-id></element-citation></ref><ref id="B32"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maron</surname><given-names>DM</given-names></name><name name-style="western"><surname>Ames</surname><given-names>BN</given-names></name></person-group><year>1983</year><article-title>Revised methods for the Salmonella mutagenity
test</article-title><source>Mutat Res</source><volume>113</volume><fpage>173</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">6341825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-1161(83)90010-9</pub-id></element-citation></ref><ref id="B33"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maya</surname><given-names>JD</given-names></name><name name-style="western"><surname>Bollo</surname><given-names>S</given-names></name><name name-style="western"><surname>Nu&#241;ez-Vergara</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Squella</surname><given-names>JA</given-names></name><name name-style="western"><surname>Repetto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Morello</surname><given-names>A</given-names></name><name name-style="western"><surname>P&#233;ri&#233;</surname><given-names>J</given-names></name><name name-style="western"><surname>Chauvi&#232;re</surname><given-names>G</given-names></name></person-group><year>2003</year><article-title>Trypanosoma cruzi: effect and mode of action of
nitroimidazole and nitrofuran derivatives</article-title><source>Biochem Pharmacol</source><volume>65</volume><fpage>999</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">12623132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-2952(02)01663-5</pub-id></element-citation></ref><ref id="B34"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mello</surname><given-names>FVC</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>AS</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>MM</given-names></name><name name-style="western"><surname>Boechat</surname><given-names>N</given-names></name><name name-style="western"><surname>Aiub</surname><given-names>CAF</given-names></name><name name-style="western"><surname>Felzenszwalb</surname><given-names>I</given-names></name></person-group><year>2013</year><article-title>Evaluation of genotoxic effects of new molecules with
possible trypanocidal activity for Chagas disease treatment</article-title><source>Scientific World Journal</source><volume>2013</volume><fpage>287</fpage><lpage>319</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/287319</pub-id><pub-id pub-id-type="pmcid">PMC3842072</pub-id><pub-id pub-id-type="pmid">24311974</pub-id></element-citation></ref><ref id="B35"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mital</surname><given-names>A</given-names></name></person-group><year>2009</year><article-title>Synthetic nitroimidazoles: biological activities and
mutagenicity relationships</article-title><source>Sci Pharm</source><volume>77</volume><fpage>497</fpage><lpage>520</lpage></element-citation></ref><ref id="B36"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreth</surname><given-names>M</given-names></name><name name-style="western"><surname>Ornelas</surname><given-names>D</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>CRB</given-names></name><name name-style="western"><surname>Souza</surname><given-names>MVN</given-names></name></person-group><year>2010</year><article-title xml:lang="pt">Nitroimidaz&#243;is - uma promissora classe de subst&#226;ncias
para o tratamento da tuberculose</article-title><source>Rev Virtual Quim</source><volume>2</volume><fpage>105</fpage><lpage>117</lpage></element-citation></ref><ref id="B37"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nesslany</surname><given-names>F</given-names></name><name name-style="western"><surname>Brugier</surname><given-names>S</given-names></name><name name-style="western"><surname>Mouries</surname><given-names>M</given-names></name><name name-style="western"><surname>Le Curieux</surname><given-names>F</given-names></name><name name-style="western"><surname>Marzin</surname><given-names>D</given-names></name></person-group><year>2004</year><article-title>In vitro and in vivo chromosomal aberrations induced by
megazol</article-title><source>Mutat Res</source><volume>560</volume><fpage>147</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">15157652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mrgentox.2004.02.013</pub-id></element-citation></ref><ref id="B38"><element-citation publication-type="report"><person-group person-group-type="author"><collab>OECD iLibrary - Organisation for Economic Cooperation and
Development</collab></person-group><year>1997</year><source>OECD Guidelines for the Testing of Chemicals, Section 4. Test
No. 471: Bacterial Reverse Mutation Test</source><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en">oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en</ext-link></comment></element-citation></ref><ref id="B39"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patterson</surname><given-names>S</given-names></name><name name-style="western"><surname>Wyllie</surname><given-names>S</given-names></name></person-group><year>2014</year><article-title>Nitro drugs for the treatment of try- panosomatid
diseases: past, present and future prospects</article-title><source>Trends Parasitol</source><volume>30</volume><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">24776300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pt.2014.04.003</pub-id><pub-id pub-id-type="pmcid">PMC4045206</pub-id></element-citation></ref><ref id="B40"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>AK</given-names></name><name name-style="western"><surname>Abdel-Nabi</surname><given-names>H</given-names></name></person-group><year>2007</year><article-title>Cancer imaging agents for positron emission tomography:
beyond FDG</article-title><source>Curr Med Imaging Rev</source><volume>3</volume><fpage>178</fpage><lpage>185</lpage></element-citation></ref><ref id="B41"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paula</surname><given-names>FR</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>SHP</given-names></name><name name-style="western"><surname>Tavares</surname><given-names>LC</given-names></name></person-group><year>2009</year><article-title xml:lang="pt">Aspectos mecan&#237;sticos da bioatividade e toxicidade de
nitrocompostos</article-title><source>Qu&#237;mica Nova</source><volume>32</volume><fpage>1013</fpage><lpage>1020</lpage></element-citation></ref><ref id="B42"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poli</surname><given-names>P</given-names></name><name name-style="western"><surname>Mello</surname><given-names>MA</given-names></name><name name-style="western"><surname>Buschini</surname><given-names>A</given-names></name><name name-style="western"><surname>Mortara</surname><given-names>RA</given-names></name><name name-style="western"><surname>Albuquerque</surname><given-names>CN</given-names></name><name name-style="western"><surname>Silva</surname><given-names>S</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>C</given-names></name><name name-style="western"><surname>Zucchi</surname><given-names>TMAD</given-names></name></person-group><year>2002</year><article-title>Cytotoxic and genotoxic effects of megazol, an
anti-Chagas disease drug, assessed by different short-term tests</article-title><source>Biochem Pharmacol</source><volume>64</volume><fpage>1617</fpage><lpage>1627</lpage><pub-id pub-id-type="pmid">12429351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-2952(02)01390-4</pub-id></element-citation></ref><ref id="B43"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenkranz</surname><given-names>HS</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Speck</surname><given-names>WT</given-names></name><name name-style="western"><surname>Stambaugh</surname><given-names>JE</given-names></name></person-group><year>1976</year><article-title>Mutagenicity of metronidazole: structure-activity
relationships</article-title><source>Mutat Res</source><volume>38</volume><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">778605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-1161(76)90191-6</pub-id></element-citation></ref><ref id="B44"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salom&#227;o</surname><given-names>K</given-names></name><name name-style="western"><surname>Souza</surname><given-names>EM</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>AS</given-names></name><name name-style="western"><surname>Silva</surname><given-names>EF</given-names></name><name name-style="western"><surname>Fraga</surname><given-names>CAM</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>HS</given-names></name><name name-style="western"><surname>Castro</surname><given-names>SL</given-names></name></person-group><year>2010</year><article-title>In vitro and in vivo activity of
1,3,4-thiadiazole-2-arylhydrazone derivatives of megazol on Trypanosoma
cruzi</article-title><source>Antimicrob Agents Chemother</source><volume>54</volume><fpage>2023</fpage><lpage>2031</lpage><pub-id pub-id-type="pmid">20231395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01241-09</pub-id><pub-id pub-id-type="pmcid">PMC2863677</pub-id></element-citation></ref><ref id="B45"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmunis</surname><given-names>GA</given-names></name><name name-style="western"><surname>Yadon</surname><given-names>ZE</given-names></name></person-group><year>2010</year><article-title>Chagas disease: a Latin American health problem becoming
a world health problem</article-title><source>Acta Trop</source><volume>115</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">19932071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actatropica.2009.11.003</pub-id></element-citation></ref><ref id="B46"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silvestri</surname><given-names>R</given-names></name><name name-style="western"><surname>Artico</surname><given-names>M</given-names></name><name name-style="western"><surname>Martino</surname><given-names>G</given-names></name><name name-style="western"><surname>Ragno</surname><given-names>R</given-names></name><name name-style="western"><surname>Massa</surname><given-names>S</given-names></name><name name-style="western"><surname>Loddo</surname><given-names>R</given-names></name><name name-style="western"><surname>Murgioni</surname><given-names>C</given-names></name><name name-style="western"><surname>Loi</surname><given-names>AG</given-names></name><name name-style="western"><surname>La Colla</surname><given-names>P</given-names></name><name name-style="western"><surname>Pani</surname><given-names>A</given-names></name></person-group><year>2002</year><article-title>Synthesis, biological evaluation and binding mode of
novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1
reversed transcriptase</article-title><source>J Med Chem</source><volume>45</volume><fpage>1567</fpage><lpage>1576</lpage><pub-id pub-id-type="pmid">11931611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm010904a</pub-id></element-citation></ref><ref id="B47"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skupin</surname><given-names>R</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>TG</given-names></name><name name-style="western"><surname>Frohlich</surname><given-names>R</given-names></name><name name-style="western"><surname>Prigge</surname><given-names>J</given-names></name><name name-style="western"><surname>Haufe</surname><given-names>G</given-names></name></person-group><year>1997</year><article-title>Lipase-catalyzes resolution of both enantiomers of
ornidazole and some analogues</article-title><source>Tetrahedron Asymmetry</source><volume>8</volume><fpage>2453</fpage><lpage>2464</lpage></element-citation></ref><ref id="B48"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soeiro</surname><given-names>MNC</given-names></name><name name-style="western"><surname>Castro</surname><given-names>SL</given-names></name></person-group><year>2011</year><article-title>Screening of potential anti-Trypanosoma cruzi
candidates: In vitro and in vivo studies</article-title><source>Open Med Chem J</source><volume>5</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">21629508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1874104501105010021</pub-id><pub-id pub-id-type="pmcid">PMC3103897</pub-id></element-citation></ref><ref id="B49"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speit</surname><given-names>G</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>A</given-names></name></person-group><year>2006</year><article-title>The comet assay: a sensitive genotoxicity test for the
detection of DNA damage and repair</article-title><source>Methods Mol Biol</source><volume>314</volume><fpage>275</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">16673888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1385/1-59259-973-7:275</pub-id></element-citation></ref><ref id="B50"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torreele</surname><given-names>E</given-names></name><name name-style="western"><surname>Trunz</surname><given-names>BB</given-names></name><name name-style="western"><surname>Tweats</surname><given-names>D</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>M</given-names></name><name name-style="western"><surname>Brun</surname><given-names>R</given-names></name><name name-style="western"><surname>Mazu&#233;</surname><given-names>G</given-names></name><name name-style="western"><surname>Bray</surname><given-names>MA</given-names></name><name name-style="western"><surname>P&#233;coul</surname><given-names>B</given-names></name></person-group><year>2010</year><article-title>Fexinidazole - a new oral nitroimidazole drug candidate
entering clinical development for the treatment of sleeping
sickness</article-title><source>PLoS Negl Trop Dis</source><volume>4</volume><elocation-id/><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0000923</pub-id><pub-id pub-id-type="pmcid">PMC3006138</pub-id><pub-id pub-id-type="pmid">21200426</pub-id></element-citation></ref><ref id="B51"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urbina</surname><given-names>JA</given-names></name></person-group><year>2014</year><article-title>Recent clinical trials for the etiological treatment of
chronic Chagas disease: advances, challenges and perspectives</article-title><source>J Eukaryot Microbiol</source><volume>62</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">25284065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jeu.12184</pub-id></element-citation></ref><ref id="B52"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valdez</surname><given-names>C</given-names></name><name name-style="western"><surname>Tripp</surname><given-names>JC</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kalisiak</surname><given-names>J</given-names></name><name name-style="western"><surname>Hruz</surname><given-names>P</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>YS</given-names></name><name name-style="western"><surname>Brown</surname><given-names>SE</given-names></name><name name-style="western"><surname>Kangas</surname><given-names>K</given-names></name><name name-style="western"><surname>Arzu</surname><given-names>LV</given-names></name><name name-style="western"><surname>Davids</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Gillin</surname><given-names>FD</given-names></name><name name-style="western"><surname>Upcroft</surname><given-names>JA</given-names></name><name name-style="western"><surname>Upcroft</surname><given-names>P</given-names></name><name name-style="western"><surname>Fokin</surname><given-names>VV</given-names></name><name name-style="western"><surname>Smith</surname><given-names>DK</given-names></name><name name-style="western"><surname>Sharpless</surname><given-names>KB</given-names></name><name name-style="western"><surname>Eckmann</surname><given-names>L</given-names></name></person-group><year>2009</year><article-title>Synthesis and electrochemistry of 2-ethenyl and
2-ethanyl derivatives of 5-nitroimidazole and antimicrobial activity against
Giardia lamblia</article-title><source>J Med Chem</source><volume>52</volume><fpage>4038</fpage><lpage>4053</lpage><pub-id pub-id-type="pmid">19480409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm900356n</pub-id><pub-id pub-id-type="pmcid">PMC2766634</pub-id></element-citation></ref><ref id="B53"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viod&#233;</surname><given-names>C</given-names></name><name name-style="western"><surname>Bettache</surname><given-names>N</given-names></name><name name-style="western"><surname>Cenas</surname><given-names>N</given-names></name><name name-style="western"><surname>Krauth-Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Chauvi&#232;re</surname><given-names>G</given-names></name><name name-style="western"><surname>Bakalara</surname><given-names>N</given-names></name><name name-style="western"><surname>P&#233;ri&#233;</surname><given-names>J</given-names></name></person-group><year>1999</year><article-title>Enzymatic reduction studies of
nitroheterocycles</article-title><source>Biochem Pharmacol</source><volume>57</volume><fpage>549</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">9952319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-2952(98)00324-4</pub-id></element-citation></ref><ref id="B54"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voogd</surname><given-names>CE</given-names></name><name name-style="western"><surname>van der Stel</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>JJ</given-names></name></person-group><year>1979</year><article-title>The mutagenic action of nitroimidazoles. IV. A
comparison of the mutagenic action of several nitroimidazoles and some
imidazoles</article-title><source>Mutat Res</source><volume>66</volume><fpage>207</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">375080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-1218(79)90082-x</pub-id></element-citation></ref><ref id="B55"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>JS</given-names></name><name name-style="western"><surname>Miwa</surname><given-names>GT</given-names></name></person-group><year>2011</year><article-title>Bioactivation of drugs: risk and drug
design</article-title><source>Annu Rev Pharmacol Toxicol</source><volume>51</volume><fpage>145</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">21210745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pharmtox-010510-100514</pub-id></element-citation></ref><ref id="B56"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>JS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Bagan</surname><given-names>E</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Wislock</surname><given-names>P</given-names></name><name name-style="western"><surname>Miwa</surname><given-names>GT</given-names></name></person-group><year>1987</year><article-title>Structural alterations that differentially affect the
mutagenic and antitrichomonal activities of 5-nitroimidazoles</article-title><source>J Med Chem</source><volume>30</volume><fpage>150</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">3543363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm00384a025</pub-id></element-citation></ref><ref id="B57"><element-citation publication-type="report"><person-group person-group-type="author"><collab>WHO</collab></person-group><year>2011</year><source>17th list of essential medicines</source><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf">whqlibdoc.who.int/hq/2011/a95053_eng.pdf</ext-link></comment></element-citation></ref><ref id="B58"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>William</surname><given-names>J</given-names></name><name name-style="western"><surname>Ross</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>WB</given-names></name></person-group><year>1975</year><article-title>Antiparasitic nitroimidazoles. 8. Derivatives of
2-(4-formylstyryl)-5-nitro-1-vinylimidazole</article-title><source>J Med Chem</source><volume>18</volume><fpage>2158</fpage><lpage>2161</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm00236a009</pub-id><pub-id pub-id-type="pmid">804551</pub-id></element-citation></ref><ref id="B59"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winkelmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Raether</surname><given-names>W</given-names></name></person-group><year>1978</year><article-title>Chemotherapeutically active nitro-compounds. 4.
5-nitroimidazoles (Part III)</article-title><source>Arzneimttelforschung</source><volume>28</volume><fpage>739</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">107955</pub-id></element-citation></ref><ref id="B60"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yakugaku</surname><given-names>Z</given-names></name></person-group><year>1971</year><article-title>Studies on chemotherapeutical drugs. VII. Synthesis of
nitroimidazole derivatives. 2. Preparation of 4(or 5)-nitro-5(or
4)-styrylimidazole derivatives and 4 (or 5)-(beta-phenyl-beta-hydroxy)ethyl-5 (or
4)-nitro-imidazole derivatives and their antimicrobial activity</article-title><source>J Pharm Soc Japan</source><volume>91</volume><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1248/yakushi1947.91.2_231</pub-id><pub-id pub-id-type="pmid">5102354</pub-id></element-citation></ref><ref id="B61"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yun</surname><given-names>O</given-names></name><name name-style="western"><surname>Priotto</surname><given-names>G</given-names></name><name name-style="western"><surname>Tong</surname><given-names>J</given-names></name><name name-style="western"><surname>Flevaud</surname><given-names>L</given-names></name><name name-style="western"><surname>Chappuis</surname><given-names>F</given-names></name></person-group><year>2010</year><article-title>NECT is next: implementing the new drug combination
therapy for Trypanosoma brucei gambiense sleeping sickness</article-title><source>PLoS Negl Trop Dis</source><volume>4</volume><elocation-id/><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0000720</pub-id><pub-id pub-id-type="pmcid">PMC2876135</pub-id><pub-id pub-id-type="pmid">20520803</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>